Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline International as contract manufacturer for Mydcombi…

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Anticipates having product available to ship in January 2024 NEW YORK— November 2, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an  ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of…

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis NEW YORK— October 30, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an  ophthalmic technology company…

Eyenovia To Present Data On Preservative-Free Microbial Integrity Of The Optejet®

In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions. Presentation to be made at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual…

Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the…

Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals

APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery Further leverages Eyenovia’s Mydcombi sales force and represents additional…

Eyenovia Announces First Commercial Sale of MydCombi™

Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation Validates Eyenovia’s proprietary Optejet® dispensing platform World-renowned board-certified ophthalmologist…

Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing…

Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform

Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary development programs as well as current and future…

Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining…